Targeting the Tie2–αvβ3 integrin axis with bi-specific reagents for the inhibition of angiogenesis

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

(2017) Virginia M. Rosen et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Therapeutic targeting of the angiopoietin–TIE pathway

(2017) Pipsa Saharinen et al.   NATURE REVIEWS DRUG DISCOVERY

New Directions in Anti-Angiogenic Therapy for Glioblastoma

(2017) Nancy Wang et al.   Neurotherapeutics

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy

(2017) Tomer Shlamkovich et al.   Oncotarget

Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis

(2016) Dongheon Lee et al.   mAbs

A Designed Angiopoietin-1 Variant, Dimeric CMP-Ang1 Activates Tie2 and Stimulates Angiogenesis and Vascular Stabilization in N-glycan Dependent Manner

(2015) Nuri Oh et al.   Scientific Reports

Metal ion and ligand binding of integrin α5β1

(2014) Wei Xia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of resistance to anti-angiogenesis therapies

(2013) Sandy Giuliano et al.   BIOCHIMIE

Anti-angiogenesis in cancer therapy: Hercules and hydra

(2013) S. Bellou et al.   CANCER LETTERS

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

Complete integrin headpiece opening in eight steps

(2013) Jieqing Zhu et al.   JOURNAL OF CELL BIOLOGY

Anti-angiogenesis therapy in cancer: Current challenges and future perspectives

(2012) Farbod Shojaei   CANCER LETTERS

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

(2012) Moritz Felcht et al.   JOURNAL OF CLINICAL INVESTIGATION

Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma

(2012) Nate N. Waldron et al.   ORAL ONCOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and  v 3 integrin

(2011) N. Papo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Selective targeting of adenovirus to αvβ3 integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies

(2010) Hidde J. Haisma et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

(2010) J. L. Brown et al.   MOLECULAR CANCER THERAPEUTICS

Tie1-Tie2 Interactions Mediate Functional Differences between Angiopoietin Ligands

(2010) Tom C.M. Seegar et al.   MOLECULAR CELL

Impaired  IIb 3 Integrin Activation and Shear-Dependent Thrombus Formation in Mice Lacking Phospholipase D1

(2010) M. Elvers et al.   Science Signaling

Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis

(2009) Payaningal R. Somanath et al.   ANGIOGENESIS

Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo

(2009) Richard W.A. Luke et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic Targeting of αvβ3Integrin and Galectin-1 with Heteromultivalent Paramagnetic Liposomes for Combined MR Imaging and Treatment of Angiogenesis

(2009) Ewelina Kluza et al.   NANO LETTERS

Inhibition of In Vivo Tumor Angiogenesis and Growth Via Systemic Delivery of an Angiopoietin 2-Specific RNA Aptamer

(2008) Shiva Sarraf-Yazdi et al.   JOURNAL OF SURGICAL RESEARCH

Differential function of Tie2 at cell–cell contacts and cell–substratum contacts regulated by angiopoietin-1

(2008) Shigetomo Fukuhara et al.   NATURE CELL BIOLOGY

Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts

(2008) Pipsa Saharinen et al.   NATURE CELL BIOLOGY